Physician profile
Thomas J Lorenc
NPI 1518935048
$3,709.54
in general payments reported to CMS, 2019-2025
37 companies · $28.51 in 2025
The $28.51 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $96.17 · 2021: $467 · 2022: $1,256 · 2023: $947 · 2024: $544 · 2025: $28.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,519.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $825.08 | 2019-2024 | |
| Astellas Pharma US INC | $412.20 | 2019-2024 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $191.20 | 2023-2024 | Gemtesa, Myfembree |
| Axonics, INC. | $189.47 | 2021-2024 | Axonics, Bulkamid |
| Exeltis, USA INC. | $186.69 | 2020-2024 | Slynd |
| Coopersurgical, INC. | $185.41 | 2019-2024 | Paragard T 380a |
| Amgen INC. | $177.40 | 2020-2022 | |
| Pfizer INC. | $166.79 | 2021-2023 | |
| Therapeuticsmd, INC. | $134.86 | 2019-2022 | |
| Hologic Sales and Service, LLC | $131.18 | 2019-2025 | Myosure Tissue Removal Device, Acessa Provu System, Omni Hysteroscope |
| Aspira Women'S Health INC | $121.25 | 2022-2023 | Ova1 |
| Bayer Healthcare Pharmaceuticals INC. | $85.45 | 2021-2023 | |
| Organon LLC | $83.00 | 2022-2024 | Nexplanon |
| Biogen, INC. | $81.62 | 2024 | |
| Myovant Sciences INC. | $77.74 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $71.26 | 2022-2023 | |
| Ethicon US, LLC | $67.34 | 2021-2023 | Enseal, Stratafix, Dermabond Prineo |
| Channel Medsystems, INC. | $47.89 | 2022-2023 | |
| Evofem Biosciences, INC. | $47.08 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $43.74 | 2019-2020 | |
| Intuitive Surgical, INC. | $40.00 | 2019 | |
| Avion Pharmaceuticals | $39.74 | 2021-2022 | |
| Urovant Sciences INC | $29.73 | 2022 | |
| Shield Therapeutics INC | $29.61 | 2023 | Accrufer |
| Boston Scientific Corporation | $27.92 | 2022 | |
| Baxter Healthcare | $26.18 | 2024 | Perclot |
| Coloplast Corp | $23.36 | 2024 | |
| Duchesnay USA Incorporated | $22.14 | 2019 | |
| Mylan Pharmaceuticals INC. | $19.57 | 2022 | |
| Mycovia Pharmaceuticals, INC. | $19.00 | 2023 | Vivjoa |
| Gynesonics, INC. | $18.64 | 2022 | |
| Scynexis, INC. | $17.69 | 2021 | |
| Daiichi Sankyo INC. | $16.06 | 2019 | |
| Minerva Surgical, INC | $14.37 | 2023 | |
| Allergan, INC. | $14.19 | 2019 | |
| Exact Sciences Corporation | $13.34 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lorenc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.